See more : Saudi Home Loans Company (1183.SR) Income Statement Analysis – Financial Results
Complete financial analysis of DURECT Corporation (DRRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DURECT Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Rallis India Limited (RALLIS.BO) Income Statement Analysis – Financial Results
- Hangzhou Weiguang Electronic Co.,Ltd. (002801.SZ) Income Statement Analysis – Financial Results
- American Future Fuel Corporation (AFFCF) Income Statement Analysis – Financial Results
- Games Operators S.A. (GOP.WA) Income Statement Analysis – Financial Results
- TOYA S.A. (TOA.WA) Income Statement Analysis – Financial Results
DURECT Corporation (DRRX)
About DURECT Corporation
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.55M | 19.28M | 13.98M | 30.11M | 29.56M | 18.56M | 49.17M | 14.03M | 19.12M | 19.40M | 15.33M | 53.07M | 33.49M | 31.59M | 24.29M | 25.96M | 30.68M | 21.89M | 28.57M | 13.85M | 11.84M | 7.19M | 6.52M | 3.16M | 86.00K |
| Cost of Revenue | 1.72M | 1.59M | 1.96M | 1.41M | 4.14M | 4.26M | 6.63M | 5.29M | 3.91M | 5.69M | 4.84M | 4.65M | 4.71M | 4.28M | 5.34M | 3.37M | 3.23M | 3.25M | 2.82M | 2.73M | 2.43M | 3.09M | 3.40M | 1.29M | -272.00K |
| Gross Profit | 6.83M | 17.70M | 12.02M | 28.71M | 25.42M | 14.30M | 42.54M | 8.74M | 15.22M | 13.72M | 10.49M | 48.42M | 28.77M | 27.32M | 18.95M | 22.59M | 27.45M | 18.65M | 25.76M | 11.12M | 9.41M | 4.10M | 3.13M | 1.86M | 358.00K |
| Gross Profit Ratio | 79.91% | 91.76% | 86.01% | 95.33% | 85.99% | 77.04% | 86.51% | 62.28% | 79.58% | 70.69% | 68.44% | 91.23% | 85.93% | 86.47% | 78.01% | 87.04% | 89.49% | 85.16% | 90.15% | 80.30% | 79.49% | 57.05% | 47.92% | 59.08% | 416.28% |
| Research & Development | 29.35M | 36.86M | 31.85M | 27.71M | 30.21M | 25.50M | 31.61M | 29.27M | 24.32M | 22.43M | 18.95M | 20.27M | 34.05M | 36.21M | 34.91M | 39.41M | 38.34M | 37.24M | 28.90M | 24.23M | 20.95M | 29.55M | 24.57M | 13.34M | 6.36M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.02M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.36M | 15.92M | 14.45M | 13.61M | 14.36M | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.14M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 12.08M | 9.85M | 3.04M |
| Other Expenses | 0.00 | 23.66M | 25.52M | 3.77M | 12.08M | 17.29M | 8.03M | 27.39M | 16.49M | 14.17M | 15.36M | 0.00 | 11.69M | 16.12M | 22.45M | 48.00K | 31.00K | 424.00K | 1.21M | 1.25M | 1.34M | 1.34M | 1.84M | 1.50M | 311.00K |
| Operating Expenses | 43.72M | 52.78M | 46.30M | 41.32M | 44.57M | 37.92M | 44.77M | 41.10M | 35.88M | 34.71M | 31.65M | 32.36M | 47.63M | 51.15M | 50.05M | 68.40M | 51.99M | 50.08M | 41.38M | 35.43M | 30.69M | 43.07M | 38.50M | 24.69M | 9.72M |
| Cost & Expenses | 45.43M | 54.37M | 48.25M | 42.73M | 48.72M | 42.18M | 51.41M | 46.39M | 39.79M | 40.40M | 36.49M | 37.01M | 52.34M | 55.43M | 55.39M | 71.77M | 55.22M | 53.33M | 44.20M | 38.16M | 33.11M | 46.15M | 41.90M | 25.98M | 9.45M |
| Interest Income | 2.13M | 2.15M | 156.00K | 517.00K | 1.07M | 870.00K | 967.00K | 143.00K | 237.00K | 39.00K | 0.00 | 151.00K | 134.00K | 943.00K | 420.00K | 1.55M | 0.00 | 3.83M | 2.27M | 0.00 | 1.04M | 0.00 | 0.00 | 3.10M | 0.00 |
| Interest Expense | 2.79M | 2.40M | 2.15M | 2.24M | 2.50M | 2.57M | 2.43M | 2.29M | 2.24M | 1.15M | 290.00K | 7.00K | 46.00K | 6.00K | 36.00K | 789.00K | 2.63M | 3.44M | 4.36M | 0.00 | 2.46M | 0.00 | 0.00 | 131.00K | 0.00 |
| Depreciation & Amortization | 148.00K | 150.00K | 132.00K | 297.00K | 291.00K | 254.00K | 437.00K | 416.00K | 425.00K | 601.00K | 558.00K | 964.00K | 1.18M | 2.25M | 2.51M | 48.00K | 2.32M | 2.46M | 3.17M | 4.64M | 4.75M | 4.32M | 3.30M | 1.50M | 311.00K |
| EBITDA | -24.68M | -32.78M | -33.99M | -11.80M | -18.58M | -22.50M | -833.00K | -31.81M | -20.00M | -20.36M | -20.60M | 17.16M | -17.59M | -20.64M | -27.75M | -45.76M | -22.22M | -28.97M | -12.46M | -18.43M | -16.53M | -34.65M | -32.07M | -21.32M | -9.05M |
| EBITDA Ratio | -288.77% | -170.79% | -244.09% | -40.18% | -61.15% | -122.54% | -2.58% | -229.74% | -106.81% | -108.03% | -138.08% | 32.36% | -56.30% | -75.45% | -129.75% | -176.30% | -70.11% | -121.89% | -42.20% | -141.98% | -139.70% | -482.25% | -276.58% | -675.85% | -10,520.93% |
| Operating Income | -36.88M | -35.08M | -34.27M | -12.62M | -19.15M | -23.62M | -2.24M | -32.36M | -20.66M | -21.00M | -21.16M | 16.06M | -18.85M | -23.84M | -31.10M | -45.81M | -24.54M | -31.44M | -15.63M | -24.31M | -21.28M | -38.97M | -49.40M | -22.82M | -9.36M |
| Operating Income Ratio | -431.49% | -181.93% | -245.21% | -41.89% | -64.78% | -127.23% | -4.55% | -230.76% | -108.05% | -108.23% | -138.08% | 30.25% | -56.30% | -75.45% | -128.02% | -176.48% | -80.00% | -143.58% | -54.70% | -175.48% | -179.80% | -542.37% | -757.23% | -723.39% | -10,882.56% |
| Total Other Income/Expenses | 9.26M | -251.00K | -1.99M | -1.72M | -1.43M | -1.70M | -1.46M | -2.15M | -2.00M | -1.11M | -290.00K | 144.00K | 88.00K | 937.00K | 811.00K | 758.00K | 202.00K | -1.89M | -2.50M | -3.31M | -1.42M | 1.80M | 4.47M | 0.00 | 0.00 |
| Income Before Tax | -27.62M | -35.33M | -36.27M | -14.34M | -20.58M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.29M | -43.91M | -24.34M | -33.33M | -18.12M | -27.62M | -22.70M | -37.17M | -44.93M | 0.00 | 0.00 |
| Income Before Tax Ratio | -323.16% | -183.23% | -259.46% | -47.61% | -69.60% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -124.68% | -169.15% | -79.34% | -152.22% | -63.43% | -199.37% | -191.79% | -517.37% | -688.66% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 251.00K | 1.86M | -11.81M | 2.21M | 870.00K | 530.00K | -273.00K | -188.00K | -562.00K | -558.00K | 151.00K | -1.18M | -2.25M | -2.89M | -12.69M | -202.00K | 1.89M | 4.00K | 18.00K | 0.00 | 0.00 | 9.56M | -2.97M | -651.00K |
| Net Income | -27.62M | -35.58M | -38.13M | -2.52M | -22.79M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.72M | -45.05M | -24.34M | -33.33M | -18.13M | -27.64M | -22.70M | -37.17M | -44.93M | -19.85M | -8.71M |
| Net Income Ratio | -323.16% | -184.54% | -272.77% | -8.38% | -77.08% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -126.44% | -173.56% | -79.34% | -152.22% | -63.45% | -199.50% | -191.79% | -517.37% | -688.66% | -629.19% | -10,125.58% |
| EPS | -1.22 | -1.56 | -1.69 | -0.13 | -1.28 | -1.60 | -0.25 | -2.60 | -1.91 | -2.00 | -2.10 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -11.60 | -3.66 |
| EPS Diluted | -1.20 | -1.56 | -1.69 | -0.13 | -1.28 | -1.58 | -0.25 | -2.59 | -1.91 | -1.98 | -2.08 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -6.01 | -3.66 |
| Weighted Avg Shares Out | 26.26M | 22.78M | 22.50M | 19.95M | 17.80M | 15.84M | 14.53M | 13.27M | 11.85M | 11.06M | 10.22M | 8.84M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 1.71M | 2.38M |
| Weighted Avg Shares Out (Dil) | 26.52M | 22.78M | 22.50M | 19.95M | 17.80M | 15.98M | 14.53M | 13.32M | 11.85M | 11.17M | 10.31M | 8.86M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 3.31M | 2.38M |
DURECT Corporation: DUR-928 May Benefit COVID-19 Patients With Acute Organ Injury
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
Durect Is A Biotech To Watch With Key Catalysts In 2020
DURECT Co. (NASDAQ:DRRX) Given Consensus Rating of "Buy" by Analysts
Analysts Are Bullish on These Healthcare Stocks: Antares Pharma (ATRS), Durect (DRRX)
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More
Source: https://incomestatements.info
Category: Stock Reports